Image may be NSFW.
Clik here to view.
A panel for the FDA is slated to review Senseonics‘ (NYSE:SENS) premarket approval application for its Eversense implantable continuous glucose monitoring system on March 29.
The company’s device sends glucose data every five minutes to a transmitter, which then communicates that information to a mobile app, displaying the values in the real-time. The Eversense system also includes an alarm to warn the user if they’re approaching hyper- or hypo-glycemia.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA panel to review Senseonics’ implantable CGM this month appeared first on MassDevice.
